Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease

Clinical Thought

The diverse clinical presentations of systemic mastocytosis can complicate timely diagnosis, disease classification, and individualized treatment selection across indolent and advanced disease. This social media forum invites learners to submit questions and challenging cases for faculty guidance on applying diagnostic criteria, interpreting KIT mutation test results, assessing disease burden and risk, and selecting and sequencing therapies. The discussion will also address anaphylaxis prevention, safety monitoring, treatment response, and multidisciplinary care, helping learners apply symposium insights to patient-centered management decisions throughout the certified life of the program.

Released: November 06, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Blueprint Medicines, a Sanofi company.

Blueprint Medicines, a Sanofi company

Target Audience

This educational activity is intended for hematologists, nurse practitioners, physician assistants, nurses, pharmacists, and HCPs who may clinically encounter and care for individuals with systemic mastocytosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current diagnostic recommendations for SM to clinical practice, including ICC/WHO classification criteria, bone marrow evaluation, KIT mutation testing, serum tryptase, and immunophenotyping

  • Differentiate indolent vs advanced SM subtypes, clinical manifestations across organ systems, disease burden, and risk stratification approaches

  • Select appropriate therapies for SM patients by analyzing efficacy and safety evidence for symptomatic management, cytoreductive agents, KIT-targeted therapies, and emerging investigational approaches, considering disease subtype, patient needs, and preferences

  • Implement multidisciplinary, patient-centered management strategies including anaphylaxis prevention, shared decision-making, monitoring workflows, and care coordination across specialties

Financial Disclosures

Primary Author

Brian Chernak, MD: consultant/advisor/speaker: Cogent Biosciences, Geron, PharmaEssentia, Refined Oncology, Sobi; other financial or material support: Blueprint.

Daniel J. DeAngelo, MD, PhD: consultant/advisor/speaker: Amgen, Autolos, Blueprint, Gilead, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, Takeda; researcher: AbbVie, Blueprint, Cogent, Novartis; data and safety monitoring board: Daiichi Sankyo.

James McCloskey, MD: consultant/advisor/speaker: Blueprint, Cogent.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.